China Biologic Produ (CBPO)
$110.76 0.17 (0.15%)
15:16 EDT CBPO Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 3.01B
PE Ratio 49.45
Volume (Avg. Vol.) 65,536
Day's Range 110.00 - 110.91
52-Week Range 97.91 - 119.44
Dividend & Yield N/A (N/A)
CBPO Stock Predictions, Articles, and China Biologic Produ News
- From InvestorPlace
- From the Web
These stocks slot into any portfolio and will pack a special punch.
This week, the overall grades of 37 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The grades of 10 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
The following stocks were moving the Manufacturing sector today.
This week, 3 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").
Healthcare has been a top performing industry this year, and long-term growth in services, technological advances make these are some of the best healthcare stocks to buy for the long haul.
Healthcare stocks rose 0.5% on Wall Street on Friday.
Healthcare stocks rose broadly on Wall Street on Wednesday morning, with the sector seeing an overall increase of 0.7%.
Healthcare stocks declined on Wall Street on Tuesday, down 2.4%.
Healthcare stocks declined broadly on Wall Street on Thursday morning, with the sector seeing an overall decline of 0.4%.
Healthcare stocks rose 1.8% on Wall Street on Wednesday morning.
This week, these ten stocks, all currently earning A's ("strong buy") on Portfolio Grader, have the best year-to-date performance.
Healthcare stocks declined 0.3% on Wall Street today.
These 7 top-rated biotech stocks are priced right, and are capable of weathering the market's recent downturn.
Healthcare stocks declined 0.9% on Wall Street so far on Friday.
From Market News Video
From Seeking Alpha
China Biologic Products (CBPO -1.9%) Q2 reports total sales of $111.1M (-18.1% Y/Y).Gross profit decreased by 16.0% to $76.4M.Income from operations decreased by 11.4% to $42.7M from $48.2M last year.Non-GAAP adjusted net income decreased 10.9% to $43.4M.Non-GAAP EPS of $1.11, misses consensus.In April 2020, the company received approval from the Health Commission of Shandong Province to build a new plasma collection station in Yangxin County, Binzhou City of Shandong Province.Previously: China Biologic Products EPS misses by $0.17 (Aug.
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader